Hong Zhao - SciClone Pharmaceuticals Insider

SciClone Pharmaceuticals Inc -- USA Stock  

USD 11.10  0.050000  0.45%

CEO of China Operations

Mr. Hong Zhao was appointed as Chief Executive Officer China Operations of Sciclone Pharmaceuticals, Inc., effective April 01, 2013. Mr. Zhao joined SciClone as Chief Executive Officer, China Operations, in April 2013. Prior to SciClone, from 2011 to 2013, Mr. Zhao served as Executive Vice President of Simcere Pharmaceutical Group, a manufacturer and supplier of pharmaceuticals in China, where he was responsible for all business operations and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training and personnel development. Prior to Simcere, from 1999 to 2011, Mr. Zhao held various positions at Novartis China, a health care products company, including most recently, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai
Age: 50  CEO Since 2013      
650-358-3456  www.sciclone.com
Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School in Shanghai.

Hong Zhao Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.28 % which means that it generated profit of $11.28 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 19.56 % meaning that it created $19.56 on every $100 dollars invested by stockholders.

Similar Executives

Found 5 records

CEO Since

Brenton SaundersAllergan plc
2016
Donald DeGolyerEndo International plc
N/A
Rajiv SilvaEndo International plc
N/A
Thomas PikeQuintiles IMS Holdings Inc
2016
Paul CampanelliEndo International plc
2016

Entity Summary

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals Inc (SCLN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 590 people. SciClone Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Chance of Distress Now
   

Chance of Distress

Get analysis of equity chance of financial distress in the next 2 years
Hide  View All  Next  Launch Chance of Distress
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SciClone Pharmaceuticals Inc to your portfolio

Top Management

SciClone Pharmaceuticals Leadership Team
Charles Meng, VP
Richard Hawkins, Director
Gregg Lapointe, Director, MBA
Hong Zhao, CEO
Wilson Cheung, CFO
Nancy Chang, Director, Ph.D
Anthony Lapointe, Director, MBA
Lan Xie, CFO, MBA
Raymond Low, President, MBA
Robert King, President, Ph.D
Simon Li, Director, MBA
Jon Saxe, Chairman
Friedhelm Blobel, CEO, Ph.D

Stock Performance

SciClone Pharmaceuticals Performance Indicators